323 related articles for article (PubMed ID: 16455632)
21. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer.
Wang H; Vees H; Miralbell R; Wissmeyer M; Steiner C; Ratib O; Senthamizhchelvan S; Zaidi H
Radiother Oncol; 2009 Nov; 93(2):220-5. PubMed ID: 19767115
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
23. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer.
Verwer EE; Oprea-Lager DE; van den Eertwegh AJ; van Moorselaar RJ; Windhorst AD; Schwarte LA; Hendrikse NH; Schuit RC; Hoekstra OS; Lammertsma AA; Boellaard R
J Nucl Med; 2015 Mar; 56(3):365-71. PubMed ID: 25678491
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
25. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.
Scher B; Seitz M; Albinger W; Tiling R; Scherr M; Becker HC; Souvatzogluou M; Gildehaus FJ; Wester HJ; Dresel S
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):45-53. PubMed ID: 16932935
[TBL] [Abstract][Full Text] [Related]
26. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan.
Chen YM; Huang G; Sun XG; Liu JJ; Chen T; Shi YP; Wan LR
Nucl Med Commun; 2008 May; 29(5):425-30. PubMed ID: 18391725
[TBL] [Abstract][Full Text] [Related]
27. Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients.
Rager O; Baskin A; Amzalag G; Buchegger F; Miralbell R; Ratib O; Zilli T; Garibotto V
Nuklearmedizin; 2015; 54(5):211-6. PubMed ID: 26213186
[TBL] [Abstract][Full Text] [Related]
28. Radiation dosimetry of 18F-fluorocholine PET/CT studies in prostate cancer patients.
Fabbri C; Galassi R; Moretti A; Sintuzzi E; Mautone V; Sarti G; Strigari L; Benassi M; Matteucci F
Phys Med; 2014 May; 30(3):346-51. PubMed ID: 24238928
[TBL] [Abstract][Full Text] [Related]
29. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
30. Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer.
Sah BR; Burger IA; Schibli R; Friebe M; Dinkelborg L; Graham K; Borkowski S; Bacher-Stier C; Valencia R; Srinivasan A; Hany TF; Mu L; Wild PJ; Schaefer NG
J Nucl Med; 2015 Mar; 56(3):372-8. PubMed ID: 25678494
[TBL] [Abstract][Full Text] [Related]
31.
Abiodun-Ojo OA; Akintayo AA; Akin-Akintayo OO; Tade FI; Nieh PT; Master VA; Alemozaffar M; Osunkoya AO; Goodman MM; Fei B; Schuster DM
J Nucl Med; 2019 Nov; 60(11):1531-1536. PubMed ID: 30954940
[TBL] [Abstract][Full Text] [Related]
32. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
[TBL] [Abstract][Full Text] [Related]
33. The differential diagnostic value of dual-phase
Tian A; Lin R; Yu J; Zhang F; Zheng Q; Yuan X; Sun Z; Zhong Z
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):351-358. PubMed ID: 35422099
[TBL] [Abstract][Full Text] [Related]
34. Imaging prostate cancer with 11C-choline PET/CT.
Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
[TBL] [Abstract][Full Text] [Related]
35. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
[TBL] [Abstract][Full Text] [Related]
36. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study.
Poulsen MH; Bouchelouche K; Gerke O; Petersen H; Svolgaard B; Marcussen N; Svolgaard N; Ogren M; Vach W; Høilund-Carlsen PF; Geertsen U; Walter S
BJU Int; 2010 Sep; 106(5):639-43; discussion 644. PubMed ID: 20089104
[TBL] [Abstract][Full Text] [Related]
37. [PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence].
Lapa P; Silva R; Saraiva T; Figueiredo A; Ferreira R; Costa G; Lima JP
Acta Med Port; 2016 Mar; 29(3):182-92. PubMed ID: 27285094
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
[TBL] [Abstract][Full Text] [Related]
39. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
